|
Index | - | P/E | - | EPS (ttm) | -1.24 | Insider Own | 3.30% | Shs Outstand | 23.26M | Perf Week | -7.20% |
Market Cap | 320.53M | Forward P/E | - | EPS next Y | -2.11 | Insider Trans | -45.25% | Shs Float | 22.80M | Perf Month | -1.77% |
Income | -29.40M | PEG | - | EPS next Q | -0.36 | Inst Own | 67.40% | Short Float | 6.28% | Perf Quarter | 6.60% |
Sales | - | P/S | - | EPS this Y | -71.30% | Inst Trans | -1.72% | Short Ratio | 15.42 | Perf Half Y | -0.47% |
Book/sh | 5.05 | P/B | 2.53 | EPS next Y | -51.10% | ROA | -22.40% | Target Price | 20.33 | Perf Year | -22.05% |
Cash/sh | 4.65 | P/C | 2.74 | EPS next 5Y | - | ROE | -23.00% | 52W Range | 5.51 - 19.63 | Perf YTD | 2.24% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -35.00% | Beta | - |
Dividend % | - | Quick Ratio | 28.00 | Sales past 5Y | - | Gross Margin | - | 52W Low | 131.58% | ATR | 1.07 |
Employees | 31 | Current Ratio | 28.00 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 44.78 | Volatility | 8.45% 7.49% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | -75.00% | Profit Margin | - | Rel Volume | 1.05 | Prev Close | 13.48 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 92.83K | Price | 12.76 |
Recom | 2.00 | SMA20 | -2.35% | SMA50 | -7.84% | SMA200 | 16.58% | Volume | 96,974 | Change | -5.34% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite